triple therapy – Medxy AI

Defining and Achieving Disease Stability in COPD: Insights from Phase 3 Trials

By MedXY 09/09/2026

This article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.

Clinical Updates Gastroenterology news

Rifasutenizol-Based Triple Therapy Versus Bismuth Plus Clarithromycin Triple Therapy for First-Line Helicobacter pylori Eradication: Analysis of the EVEREST-HP Phase 3 Trial in China

By MedXY 11/24/2025

EVEREST-HP demonstrates that rifasutenizol-based triple therapy offers non-inferior H. pylori eradication with improved tolerability compared to bismuth plus clarithromycin triple therapy in treatment-naive Chinese patients.

$A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children$

Clinical Updates news Oncology Specialties

A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children

By MedXY 08/05/2025

A phase I trial published in JCO demonstrates that a novel combination of MIBG, dinutuximab, and vorinostat achieves up to 75% disease control in relapsed/refractory neuroblastoma, offering new hope for high-risk pediatric patients.